Status:
COMPLETED
Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Myasthenia Gravis
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Pathology - Generalized myasthenia gravis (MG) is cause of muscle weakness that can have a significant impact on daily life activity but can also be, when respiratory or bulbar muscles are involved, l...
Detailed Description
Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it be...
Eligibility Criteria
Inclusion
- Written consent of the patient, after informing
- Generalized MG of grade III, IV or V - Classification MGFA
- Follow-up on 15 months possible and accepted by patients
Exclusion
- Age\<18 or \>80 years
- Pregnancy
- Myasthenia of grade I or II of MGFA
- Patients already treated with prednisone or azathioprine
- Contraindication for prednisone or azathioprine
- Other associated disease requiring a treatment with prednisone or azathioprine
- Weight \>100kg
- Invasive thymoma
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2017
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT00987116
Start Date
June 1 2009
End Date
September 1 2017
Last Update
October 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Raymond Poincaré
Garches, France, 92380